Biotransformation of proteratogenic anti-epileptics in the zebrafish embryo

02:573 years ago

The zebrafish (Danio rerio) embryo has gained interest as an alternative model for developmental toxicity testing, which still mainly relies on in vivo mammalian models (e.g., rat, rabbit). However, cytochrome P450 (CYP)-mediated drug metabolism, which is critical for the bioactivation of several proteratogens, is still under debate for this model. Therefore, we investigated the potential capacity of zebrafish embryos/larvae to bioactivate two known mammalian proteratogens, carbamazepine (CBZ) and phenytoin (PHE) into their mammalian active metabolites, carbamazepine-10,11-epoxide (E-CBZ) and 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH), respectively. Zebrafish embryos were exposed to three concentrations (31.25, 85, and 250 μM) of CBZ and PHE from 51⁄4 to 120 hours post fertilization (hpf) at 28.5°C under a 14/10 hour light/dark cycle. For species comparison, also adult zebrafish, rat, rabbit and human liver microsomes (200 μg/ml) were exposed to 100 μM of CBZ or PHE for 240 minutes at 28.5°C. Potential formation of the mammalian metabolites was assessed in the embryo medium (48, 96, and 120 hpf); pooled (n=20) whole embryos/larvae extracts (24 and 120 hpf); and in the microsomal reaction mixtures (at 5 and 240 minutes) by targeted investigation using a UPLC–Triple Quadrupole MS system with lamotrigine (0.39 μM) as internal standard. Our study showed that zebrafish embryos metabolize CBZ to E-CBZ, but only at the end of organogenesis (from 96 hpf onwards), and no biotransformation of PHE to HPPH occurred. In contrast, our in vitro drug metabolism assay showed that adult zebrafish metabolize both compounds into their active mammalian metabolites. However, significant differences in metabolic rate were observed among the investigated species. These results highlight the importance of including the zebrafish in the in vitro drug metabolism testing battery
for accurate species selection in toxicity studies.

Related

The NAM Navigator: A unique repository for information on the validation and acceptance of New Approach Methodologies
Projects and initiatives
HealthToxicology

The NAM Navigator: A unique repository for information on the validation and acceptance of New Approach Methodologies

The NAM navigator is an innovative knowledge portal to navigate you to and through valuable information on the development, standardization, validation and acceptance of New Approach Methodologies (NAM). The NAM Navigator acts as an online guide that provides specific information needed in each of these steps, thereby increasing the broad use of animal-free innovations. Follow the link in the video to start navigating!
02:136 days ago
VHP4Safety project
Projects and initiatives
HealthToxicologyIn vitroIn silico

VHP4Safety project

The safety testing of chemicals and pharmaceuticals traditionally relies on animal studies. However, these raise ethical concerns and often fail to accurately predict human responses. New scientific developments offer opportunities to build a Virtual Human Platform (VHP) for safety assessment, a platform that enables assessment based solely on human physiology and biology, integrating data from in vitro and in silico models. This video explains how we are developing the VHP through an interdisciplinary approach. Read the paper in the videolink or visit or VHP4Safety (https://vhp4safety.nl/) for more information.
03:1612 days ago
AI agents for safer science: How AI is Changing Chemical Risk Assessment
Innovation examples
HealthToxicologyIn silico

AI agents for safer science: How AI is Changing Chemical Risk Assessment

This video introduces a novel approach to chemical safety, where intelligent digital agents guided by large language models support scientists in making faster, more transparent decisions. By automating complex workflows and integrating tools like the OECD QSAR Toolbox, these agentic systems help prioritise research, reduce reliance on animal testing, and pave the way for safer, more sustainable innovation.
02:5620 days ago
User Research in developing the virtual human platform
Innovation examples
ToxicologyPolicy

User Research in developing the virtual human platform

Digital tools can support the phasing out of animal-based tests and data in chemical risk assessment. This is one of the core promises of the Virtual Human Platform. The potential contribution of digitalization is linked to the acceptance and adoption of tools, methods, and data by stakeholders in several societal sectors. To facilitate the integration of stakeholders in the configuration of digital tools, Dr. Isaac Ortega Alvarado and colleagues gather insights from risk assessors in their role as users. Risk assessors are the ones who actualize chemical risk assessment and its standards through their practices. With this perspective, this research contributes to understanding the development and implementation of digital tools as embedded in social processes of construction and reception.
01:1542 days ago